Develops molecularly targeted radiation (MTR) products for cancer and rare diseases. Focuses on both diagnostic and therapeutic applications of MTR technology. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 258% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 4.5× for every dollar of annual revenue.
Analysts' average target sits 67% above today's price.
The stock trades 41% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 258% a year on average.
The company sells $893.8M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $7.9M against $893.8M in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.